28.09.2012 - German university hospital Charité and French pharma company Sanofi have agreed to expand their joint research efforts to the field of diabetes.
The partnership of the Charité and Sanofi had begun in summer 2010, initially with a focus in the field of stroke research. Following a decision on 27 September, scientists and clinicians from both sides will now work together in the field of diabetes research as well. The goal is to better understand the medical needs of patients and to find new targeted approaches to cure or treat the disease.
The partners have already agreed on a first target molecule to investigate further. Researchers from Charité discovered the yet undisclosed molecule, which will now fuel a core project at the newly founded Sanofi-Charité-diabetic laboratory. The target molecule seems to be promising, as results from laboratory tests indicate that it inhibition might protect the body from diet-and age-induced obesity and insulin resistance. “With Charité we have built a highly efficient scientific cooperation over the past two years,” said Jochen Maas, Director of Research and Development of Sanofi-Aventis Deutschland GmbH and head of the German research and development center of Sanofi.
Karl Max Einhäupl, CEO of the Charité, welcomed the enhanced cooperation as well: “Diabetes is a major challenge for our health system. Bringing together the clinical experience and the academic performance of physicians and scientists of the Charité with the development and application expertise of Sanofi, will generate valuable inputs for the development of successful diabetes therapies.”
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.
14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.